Literature DB >> 14579737

Removal of endotoxin by reverse phase HPLC abolishes anti-endothelial cell activity of bacterially expressed plasminogen kringle 5.

Andrew Dudley1, William McKinstry, David Thomas, James Best, Alicia Jenkins.   

Abstract

The success of recombinant protein expression/purification in Escherichia coli depends on a high-fidelity system rendering purified proteins free of confounding contaminants such as endotoxin. Here we report on the expression and purification of a cryptic plasminogen-derived domain, kringle 5, which was previously reported to specifically inhibit endothelial cell growth and, therefore, angiogenesis. Using a histidine (HIS)-tag expression and Ni(+)-NTA agarose purification system identical to previous reports, we found that our purified recombinant kringle 5 did inhibit endothelial cell growth, but this activity could not be eradicated by heat denaturing or proteolysis of kringle 5 with various proteases. This led us to suspect the presence of a contaminant in the purified samples. Quantitative endotoxin testing using a limulus amoebocyte lysate assay revealed that all samples purified by Ni(+)-NTA agarose alone harbored high concentrations of endotoxin that could not be removed by additional purification on anion exchange chromatography. Finally, when kringle 5 was rendered endotoxin-free by purification on reverse phase high-performance liquid chromatography (HPLC), there was a complete loss of endothelial cell growth inhibitory activity. These results strongly suggest that endotoxin-free recombinant kringle 5 may not possess anti-angiogenic activity and demonstrates that, especially in angiogenesis type assays, endotoxin contamination can lead to a misinterpretation of results.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14579737     DOI: 10.2144/03354st02

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  10 in total

1.  An autoimmune-mediated strategy for prophylactic breast cancer vaccination.

Authors:  Ritika Jaini; Pavani Kesaraju; Justin M Johnson; Cengiz Z Altuntas; Daniel Jane-Wit; Vincent K Tuohy
Journal:  Nat Med       Date:  2010-05-30       Impact factor: 53.440

2.  Endotoxin deactivation by transient acidification.

Authors:  Melina M Ribeiro; Xiumin Xu; Dagmar Klein; Norma S Kenyon; Camillo Ricordi; Maria Sueli S Felipe; Ricardo L Pastori
Journal:  Cell Transplant       Date:  2010-04-21       Impact factor: 4.064

3.  Experimental autoimmune breast failure: a model for lactation insufficiency, postnatal nutritional deprivation, and prophylactic breast cancer vaccination.

Authors:  Pavani Kesaraju; Ritika Jaini; Justin M Johnson; Cengiz Z Altuntas; Jessica J Gruden; Cagri Sakalar; Vincent K Tuohy
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

4.  High yield production of a soluble human interleukin-3 variant from E. coli with wild-type bioactivity and improved radiolabeling properties.

Authors:  Timothy R Hercus; Emma F Barry; Mara Dottore; Barbara J McClure; Andrew I Webb; Angel F Lopez; Ian G Young; James M Murphy
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

5.  Characterization of fine specificity of the immune response to a Plasmodium falciparum rhoptry neck protein, PfAARP.

Authors:  Aakanksha Kalra; Paushali Mukherjee; Virander S Chauhan
Journal:  Malar J       Date:  2016-09-07       Impact factor: 2.979

6.  Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer.

Authors:  Vincent K Tuohy; Ritika Jaini; Justin M Johnson; Matthew G Loya; Dennis Wilk; Erinn Downs-Kelly; Suparna Mazumder
Journal:  Cancers (Basel)       Date:  2016-06-16       Impact factor: 6.639

7.  Vaccination with inhibin-α provides effective immunotherapy against testicular stromal cell tumors.

Authors:  Robert Aguilar; Justin M Johnson; Patrick Barrett; Vincent K Tuohy
Journal:  J Immunother Cancer       Date:  2017-04-18       Impact factor: 13.751

8.  Regulation of Murine Ovarian Epithelial Carcinoma by Vaccination against the Cytoplasmic Domain of Anti-Müllerian Hormone Receptor II.

Authors:  Cagri Sakalar; Suparna Mazumder; Justin M Johnson; Cengiz Z Altuntas; Ritika Jaini; Robert Aguilar; Sathyamangla V Naga Prasad; Denise C Connolly; Vincent K Tuohy
Journal:  J Immunol Res       Date:  2015-11-05       Impact factor: 4.818

9.  Biological Characterization of Commercial Recombinantly Expressed Immunomodulating Proteins Contaminated with Bacterial Products in the Year 2020: The SAA3 Case.

Authors:  Sara Abouelasrar Salama; Mirre De Bondt; Nele Berghmans; Mieke Gouwy; Vivian Louise Soares de Oliveira; Sergio C Oliveira; Flavio A Amaral; Paul Proost; Jo Van Damme; Sofie Struyf; Mieke De Buck
Journal:  Mediators Inflamm       Date:  2020-07-06       Impact factor: 4.711

Review 10.  Recombinant viral proteins for use in diagnostic ELISAs to detect virus infection.

Authors:  Kelly-Anne Spencer; Fernando A Osorio; Julian A Hiscox
Journal:  Vaccine       Date:  2007-03-06       Impact factor: 3.641

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.